cyrilzakka/clinical-trials huggingface dataset:
Anatomic Features of the Neck and Preoperative Tests as Predictive Markers of Difficult Laryngoscopy

In this prospective, open cohort study the diagnostic value of tests based on neck anatomy in predicting difficult laryngoscopy was assessed.

The anatomic features of the neck measured were head extension, mouth opening, upper lip bite, Mallampati class, thyromental distance, sternomental distance, ratio of height to thyromental, neck circumference, thyrosternal distance, hyomental distance at full head extension (FHE) and at neutral position (NP), ratio of neck circumference to thyromental distance and ratio of hyomental distance FHE to hyomental distance NP.

Difficult airway assessment is based on various anatomic parameters of upper airway, much of it being concentrated on oral cavity and the pharyngeal structures. The diagnostic value of tests based on neck anatomy in predicting difficult laryngoscopy was assessed in this study .

The sample consisted of adult patients scheduled to receive general anaesthesia. Anatomic features of the neck were measured pre-operatively.

The anatomic features of the neck measured were thyromental distance, sternomental distance, ratio of height to thyromental, neck circumference, thyrosternal distance, hyomental distance at full head extension (FHE) and at neutral position (NP), ratio of neck circumference to thyromental distance and ratio of hyomental distance FHE to hyomental distance NP. The commonly used predictive tests head extension, mouth opening, upper lip bite test and Mallampati class were also measured.

The laryngoscopic view was classified according to the Cormack-Lehane Grade (1-4). Difficult laryngoscopy was defined as Cormack-Lehane Grade 3 or 4. Years of experience of the anaesthesiologists were recorded, as well as the number of tries needed to intubate the patient.

The optimal cut-off points for each predictive tests were identified by using receiver operating characteristic analysis. Sensitivity, specificity and positive predictive value and negative predictive value (NPV) were calculated for each test. Multivariate analysis with logistic regression, including all variables, was used to create a predictive model. Comparisons between genders were also performed to explore possible differences in diagnostic value and cut-off points. Finally, the years of experience of the clinician and the number of tries needed to intubate the patient were compared to assess risk of bias.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients
* BMI less than 35 kg/m2
* No known neck or airway pathology
* Scheduled for surgical procedures under general anaesthesia with tracheal intubation

Exclusion Criteria:

* Age less than 18 years
* BMI higher than 35 kg/m2
* Obvious airway malformations
* Need for rapid sequence induction/intubation under cricoid pressure
* Awake intubation
* Cervical spine pathology requiring specific manipulation
* Obstetric cases
Protein Intake and Resistance Training in Aging

Resistance training combined with protein or amino acids supplementation has been shown to be promising for mitigating age-related disabilities and comorbidities. Randomized controlled trials supporting this possibility are still scarce. These series of clinical trials aim to investigate the chronic effects of different strategies of protein and derivatives supplementation in association with resistance training on selected health-related parameters in pre-frail and frail elderly.This is a 16-month, double-blind, randomized, placebo-controlled, parallel-group clinical trial involving a series of investigations. Participants will be divided into nine groups, allowing the assessement of the effects of (1) isolated leucine supplementation; (2) protein source (whey vs. soy); (3) combination of whey protein and creatine; and (4) sexual dimorphism to the response of protein intake plus resistance training (men vs. women). All participants will undergo a supervised, resistance training program.


Eligibility Criteria:
Inclusion Criteria:

* elderly people
* frailty or pre-frailty, according to Fried et al., (2001) criteria.

Exclusion Criteria:

* on exogenous insulin and steroid-based drugs
* chronic obstructive pulmonary disease or respiratory failure
* use of protein and /or amine-based dietary supplements
* on restrictive diets (e.g. calorie or food group restrictions)
* on resistance training
* untreated cardiovascular, metabolic, or other chronic disease
* any musculoskeletal condition precluding resistance training
Hypermethylation of VTRNA2-1 Promoter in HCC Outcome

The clinic-pathological data were retrieved from the cancer registry database from the Cancer Center of Chang Gung Memorial Hospital, Linkou branch. Of the 92 HCC patients with partial hepatectomies enrolled. The biological specimen was studied with approval.

This study was approved by the Institute Review Board (IRB) of Chang Gung Memorial Hospital, Linkou Branch (IRB 201801969B0). The clinic-pathological data were retrieved from the cancer registry database from the Cancer Center of Chang Gung Memorial Hospital, Linkou branch. Of the 92 HCC patients with partial hepatectomies enrolled, all patients had curative hepatectomy and those with different cancers were excluded. HCC tumor tissue and normal tissue, 3 cm from the tumor margin, were stored immediately in a -80 degree freezer at the Central Biobank of Chang Gung Memorial Hospital. The personal information was protected with decoding and registered with number.

Eligibility Criteria:
Inclusion Criteria:

subjects with pathologic diagnosis of hepatocellular carcinoma curative partial hepatectomies

Exclusion Criteria:

history of different malignant disease. subjects cannot be treated with curative surgery.
Avastin and Taxotere for Esophagogastric Cancer

The purpose of this study is to determine what effects (good and bad) bevacizumab (Avastin) and docetaxel (Taxotere), used in combination, have on metastatic gastric and esophageal cancer.

Bevacizumab will be administered intravenously in an outpatient clinic once a week, every other week. Docetaxel will also be administered intravenously in the outpatient clinic once a week for three out of four weeks. Blood tests and vital signs will be performed weekly.

After the first eight weeks of therapy a CT scan will be performed to determine and assess the progress of the disease. If therapy is continued, radiological procedures will be performed at week 16 and every 8 weeks thereafter.

Treatment will be given for a minimum of 8 weeks, as long as the patient does not experience unacceptable side effects. Chemotherapy will continue for a year and a half as long as the cancer is responding and there are no unacceptable side effects.

Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed, unresectable or metastatic stage IV esophageal or gastric carcinoma
* Measurable disease greater than or equal to 1cm by spiral computed tomography (CT) scan or greater than or equal to 2cm by other radiographic technique
* ECOG performance status 0-2
* One prior chemotherapy for metastatic disease permitted
* White blood cell count greater than or equal to 3,000/mm
* Absolute neutrophil count greater than or equal to 1,500/mm3
* Platelet count greater than or equal to 100,000/mm3
* Hemoglobin greater than or equal to 8.0g/dl
* Creatinine less than 2.0mg/dL
* Total bilirubin less than 1.9mg/dL

Exclusion Criteria:

* Pregnant or lactating women
* History or evidence of central nervous system (CNS) disease
* Other active malignancies other than non-melanoma skin cancer or in-situ cervical cancer
* History of severe hypersensitivity to docetaxel, bevacizumab or drugs formulated with polysorbate 80.
* Current, recent or planned treatment with standard chemotherapy, radiation therapy or another experimental therapy.
* History of other disease or metabolic dysfunction.
* Serious, non-healing wound, ulcer, or bone fracture.
A Feasibility Study to Evaluate The Effect of the Electronic Patient Visit Assessment On Pain and Quality of Life for Patients With Head and Neck Cancer (HNC)

This randomized, non-blinded, phase 0/I study will assess the feasibility of conducting a large randomized clinical trial to evaluate the efficacy of the ePVA to improve pain management and HRQoL in HNC. Thirty participants undergoing radiation therapy (RT) (with or without chemotherapy) will be randomized to: 1) ePVA intervention or 2) usual care. The intervention consists of participants completing the ePVA every other week during radiation therapy (RT), then weeks 4, 12, and 24 after end of RT. Automated reports of ePVA data, including pain reports and patient-reports of pain medications, will be sent to providers to inform their clinical decisions.


Eligibility Criteria:
Inclusion Criteria:

To be eligible to participate in this study, an individual must meet all of the following criteria:

1. Histologically diagnosed HNC
2. Undergoing RT with or without chemotherapy,
3. English speaking,
4. aged 18 years or older.

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Unable to attend scheduled appointment due to geographical, social or mental reseaons,
2. In the opinion of the investigator, is unable or unlikely to comply fully with the study requirements or procedures for any reason (e.g. cognitve or physical impairment).
EMR Outcomes: Anxiety and Depression in Epilepsy

The purpose of this research is to find out how people with epilepsy and possible symptoms of anxiety or depression are doing for 6 months after a regular epilepsy clinic visit. Participants in this study will complete questionnaires either by phone or via the patient portal.

This is a study among N=30 individuals with epilepsy and high or borderline anxiety or depression symptoms receiving usual care at the Wake Forest Comprehensive Epilepsy Center. Participants are randomized to one of two outcome assessment methods \[Electronic Medical Record (EMR)-based-interventional method vs. telephone-based-standard method\] for collecting quality of life, anxiety and depression outcomes at 3 and 6 months, under usual care management.

The primary aim of the study is to assess feasibility of EMR-based outcome assessment by measuring 6-month retention.

Eligibility Criteria:
Inclusion Criteria:

* Age 18 or older
* Completed electronic questionnaires independently in clinic
* Epilepsy diagnosis (clinician impression or EEG-based)
* Borderline or high anxiety or depression symptoms at baseline
* GAD-7 score \> 7 (anxiety)
* NDDI-E score \> 13 (depression)

Exclusion Criteria:

* Passive suicidal ideation (NDDI-E item 4 score of 3 or 4)
* Age \<18 years
IL-32 Isoforms Levels in GCF and Plasma of the Patients With Periodontitis

Interleukin (IL)-32, which has been recently reported to be associated with periodontitis, has been suggested to have pleiotropic effect due to its 9 different isoforms. The aim of this study was to investigate the levels of IL-32α, IL-32β, IL-32γ, IL-32δ isoforms in gingival crevicular fluid (GCF) and plasma before and after nonsurgical periodontal treatment in patients with periodontitis (P).Twenty-seven P and 27 periodontally healthy controls (C) were recruited in this study. Periodontitis patients were performed nonsurgical periodontal treatment. GCF and plasma sampling and clinical periodontal parameters were evaluated before and 1 month after treatment. Enzyme-linked immunosorbent assay was used to analyze the levels of IL-32α, IL-32β, IL-32γ, IL-32δ isoforms in GCF and plasma samples.


Eligibility Criteria:
Inclusion Criteria:

* Have at least 20 natural teeth, excluding third molars.
* Periodontitis patients had at least two non-adjacent sites per quadrant with probing depth (PD) ≥ 5 mm and clinical attachment level (CAL) ≥ 5 mm with gingival inflammation, and alveolar bone loss affecting \>30% of the teeth, as detected on clinical and radiographical examinations.
* Periodontally healthy control group had no sign of gingival inflammation, no PD \> 3mm and no evidence of attachment or bone loss

Exclusion Criteria:

* History of systemic disease.
* Regular use of any drugs which can effect the immune system or inflammatory response in the 6 months preceding the start of the study.
* Periodontal treatment during last 6 months that could affect periodontal status.
* Smoking.
* History of radiotherapy or chemotherapy.
* Current pregnancy, lactation or menopause.
Discovery of New Early Detection Biomarkers From Peripheral Blood of Acute Respiratory Distress Syndrome(ARDS)

Acute respiratory distress syndrome (ARDS) has a very poor prognosis and high mortality. To improve the early diagnosis of ARDS, there is an urgent need for novel biomarkers of ARDS. This project aims to detect novel biomarkers from peripheral blood , which can improve the early diagnosis and develop a more efficient therapy to enhance ARDS patient survival rate. Clinical data and blood sample were recorded before treatment and after treatment. Acute Physiology And Chronic Health Evaluation III (APACHE III) scores were calculated at enrolment. Different kinds of lymphocytes from blood samples would be detected by flow cytometry ,which could be used for discovering high sensitivity and specificity ARDS biomarker.

Background Acute respiratory distress syndrome (ARDS) has a very poor prognosis and high mortality. To improve the early diagnosis of ARDS, there is an urgent need for novel biomarkers of ARDS. This project aims to detect novel biomarkers from peripheral blood , which can improve the early diagnosis and develop a more efficient therapy to enhance ARDS patient survival rate. Clinical data and blood sample were recorded before treatment and after treatment. Acute Physiology And Chronic Health Evaluation III (APACHE III) scores were calculated at enrolment. Different kinds of lymphocytes from blood samples would be detected by flow cytometry ,which could be used for discovering high sensitivity and specificity ARDS biomarker.

Eligibility Ages Eligible for Study: 18 years and older Genders Eligible for Study: Both Accepts Healthy Volunteers: Yes Sampling Method: Probility Samples

Study Population Patients who have ARDS and admitted in hospital

Primary Outcome Measures:

ILC2 and ILC3 number from peripheral blood of ARDS patients

Secondary Outcome Measures:

APACHE III score \[ Time Frame: baseline, 1week, 2 weeks \] PaO2/FiO2 ratio\[ Time Frame: baseline, 1week, 2 weeks \] Mortality or multi-organ failure \[ Time Frame: 1 month \]

Groups:

1. Mild ARDS PaO2/FiO2=201～300 mmHg，and PEEP or CPAP≤5 cm
2. Moderate ARDS PaO2/FIO2=101～200 mmHg，and PEEP≥5 cm H2O
3. Severe ARDSPaO2/FIO2≤100 mmHg，and PEEP≥10 cm H2O
4. Healthy

Eligibility Criteria:
Inclusion Criteria:

* Ages Eligible for Study: 18 years and older Genders Eligible for Study: Both Accepts Healthy Volunteers: Yes Sampling Method: Probility Samples Study Population：Patients who have ARDS and admitted in hospital Criteria：Inclusion Criteria:The Berlin definition of acute respiratory distress syndrome,ATS definition of severe pneumonia

Exclusion Criteria:

* age below 18 years,pregnancy,Expected survival under 24 hours
Effects of Talampanel on Patients With Advanced Parkinson's Disease

The purpose of this research study is to test the safety and effectiveness of the study drug, Talampanel, when used to treat patients with involuntary movements known as dyskinesias, as a result of treatment to Parkinson's disease.

It is not clear why people with Parkinson's disease develop involuntary movements (dyskinesias) but studies show that blocking receptors in the brain for a chemical called glutamate decreases these movements. Talampanel is a drug which blocks these receptors.


Eligibility Criteria:
Inclusion Criteria:

* Troublesome on-period dyskinesias as defined by a Unified Parkinson's Disease Rating Scale (UPDRS) dyskinesia sub-score \>25% of Duration of dyskinesia during waking hours and 33 must have moderate disability
* Lang-Fahn dyskinesia rating score more than 2 for at least two of the 5 tasks
* Must have Dyskinesia on average 25% of waking hours/day based on Patient Diaries
* Have been diagnosed with Parkinson's disease \> 5 years at Screening

Exclusion Criteria:

* Previous surgical therapies for PD
* Isolated or predominantly diphasic dyskinesias
* Moderate Dementia
* On disallowed concomitant medications including CYP3A4 inhibitors and inducers, amantadine, etc.
Safety and Efficacy of Propionate for Reduction of LDL Cholesterol

The objective of the trial is to evaluate a potential impact of food supplements with the short chain fatty acid propionate on blood LDL cholesterol level.

62 patients with low cardiovascular risk will be 1:1 randomized to receive either placebo (b.i.d.) or 500mg of propionate (b.i.d.). The primary endpoint is the change (delta) in blood LDL cholesterol levels after 8 weeks.

Eligibility Criteria:
Inclusion Criteria:

* patients with hypercholestrolemia and a LDL serum level of \> 115 mg/dl
* age of patient between 20 and 70 years
* participant is fully competent and has given his/her written informed consent to the scheduled trial conduct

Exclusion Criteria:

* patients with acute coronary syndrome in the last 4 weeks
* patients with chronic symptomatic heart failure (NYHA 2-4)
* patients with chronic renal failure and a GFR \< 45 ml/min
* patients with chronic liver disease
* patients with hematological diseases
* patients with severe diseases of other organ systems (tumors, infections)
* pregnancy
Whipple Protein Study

Study investigators aim to assess the effect of providing high-protein nutritional supplementation before and after surgery

Pancreaticoduodenectomy (PD) is a complex and morbid operation that is associated with many potential complications. Many people undergoing PD are malnourished due to their underlying medical condition or difficulties eating in the face of abdominal pain or obstruction from pancreatic disease. This study aims to assess the effect of high-protein dietary supplementation in improving perioperative nutrition and decreasing complications. We will randomize PD patients to an experimental arm in which they take a nutritional, high-protein supplement for 2 weeks before and after surgery, or to a control arm, where they will take a standard postoperative diet without supplementation. Outcomes and nutritional parameters will be examined after they complete the supplements.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing pancreaticoduodenectomy
* Patients aged 18 years and older
* Patients able to provide written informed consent
* Patients able to understand and comply with study guidelines
* Patients able to tolerate oral intake
* Patients who are malnourished or at risk of malnutrition as defined by a score less than 12 on the Mini-Nutritional Assessment

Exclusion Criteria:

* Patients with a milk protein allergy
* Patients with a vegan diet
* Patients dependent on artificial enteral feeding
* Patients with end-stage renal disease undergoing dialysis
* Patients who are pregnant
* Patients with ongoing eating disorder or condition precluding oral intake
* Patients who are scheduled for pancreaticoduodenectomy but are unable to receive this surgery
Effectiveness of Targeted Educational Interventions at Increasing HPV Vaccine Acceptability and Uptake

This study aims to assess the effectiveness of targeted educational interventions in increasing the acceptability and knowledge of the HPV vaccine among females ages 12 through 26. Subjects will be randomized to one of three study arms (no intervention, viewing an educational video or reading an educational handout) and then a questionnaire will be administered to assess knowledge and acceptability of the HPV vaccine. Subject charts will be reviewed to assess for initiation of the HPV vaccine.


Eligibility Criteria:
Inclusion Criteria:

1. Females ages greater than or equal to 12 years and less than or equal to 26 years
2. Presenting to a gynecology clinic for a routine or problem visit
3. Ability to read and write

Exclusion Criteria:

1. Women ages less than or greater than 12 years or greater than 26 years
2. Women with known cervical cancer
3. Known pregnancy
4. Prior initiation or completion of the HPV vaccine series
Evaluation of Healthcare Waste Management Practices and Problems Among Primary and Secondary Hospitals

Healthcare waste is defined as the total waste stream from a healthcare facility. Most of it (75-90%) is similar waste to domestic waste and is known as healthcare general waste and is made up of paper, plastic packaging, food preparation etc. But as a similar proportion (10-25%) is hazards waste and requires special treatment. If these two categories of wastes are not separated properly then the entire volume of healthcare waste is considered as infectious and hazardous to human health and can result in disease and injury so it is necessary to set up a safe and integrated management system.

In this cross-sectional study public hospitals of Mianwali City will be selected by simple random sampling for observation of practices of hospital waste management.

The data will be collected through structured Questionnaire and possibly on-sit Quantitative data on waste management practices, types of waste, compliance with regulations, and perceived challenges.

Eligibility Criteria:
Inclusion Criteria:

* Operation theatre Staff
* intensive care staff and labour room staff and laboratory room staff will be included.
* Doctors, Nurses, Nursing assistants, OT Technician, Maid's helpers, and sanitary workers.

Exclusion Criteria:

* Management staff will be excluded.
Preoperative Carbohydrate Loading in Patients Undergoing Day-case Cholecystectomy

Background: Preoperative carbohydrate loading has been shown to reduce preoperative discomfort and postoperative nausea and vomiting in general surgical patients. Few studies have been focused on patients undergoing day-case surgery.

Objective: The aim of this prospective randomized study was to determine whether preoperative carbohydrate loading enhanced the recovery of patients undergoing day-case cholecystectomy.

Design: A randomised controlled trial. Setting: Secondary care in a district general and a university hospital in Finland between 2013-2016.

Patients: A total of 113 patients ASA physical status I or II (18-70 yr) undergoing day-case cholecystectomy were included in the study. Exclusion criteria were bleeding or coagulation disorders, BMI \>40, dementia, insulin-treated diabetes, migraine, Meniere's disease or a history of alcohol or drug abuse.

Intervention: The carbohydrate rich drink (CHD) group received oral carbohydrate (200 ml) 2-3 h before surgery, and the control (Fasting) group fasted from midnight according to standard protocol.

Main outcome measures: Visual analogue scales (VAS) were used to score six discomfort parameters. The needs for analgesia or antiemetics, the time to drinking, eating and first mobilization after surgery, and the time to discharge and hospital readmission were recorded.


Eligibility Criteria:
Inclusion Criteria:

* Patients between 18-70 yr (ASA physical status I-II) eligible for day-case cholecystectomy

Exclusion Criteria:

* Patients with bleeding or coagulation disorders, BMI \>40, dementia or suffering from insulin-treated diabetes, migraine, Meniere's disease or with history of alcohol or drug abuse